198 related articles for article (PubMed ID: 28231796)
1. Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6.
Qi Y; Pradipta AR; Li M; Zhao X; Lu L; Fu X; Wei J; Hsung RP; Tanaka K; Zhou L
J Exp Clin Cancer Res; 2017 Feb; 36(1):35. PubMed ID: 28231796
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo cancer cell apoptosis triggered by competitive binding of Cinchona alkaloids to the RING domain of TRAF6.
Qi Y; Zhao X; Chen J; Pradipta AR; Wei J; Ruan H; Zhou L; Hsung RP; Tanaka K
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1011-1026. PubMed ID: 31074699
[TBL] [Abstract][Full Text] [Related]
3. N6-Isopentenyladenosine promoted HeLa cell apoptosis through inhibitions of AKT and transforming growth factor β-activated kinase 1 activation.
Li M; Qi Y; Wei J; Lu L; Zhao X; Zhou L
Tumour Biol; 2017 Mar; 39(3):1010428317695966. PubMed ID: 28345459
[TBL] [Abstract][Full Text] [Related]
4. Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor‑associated factor 6‑AKT interaction.
Liu W; Qi Y; Liu L; Tang Y; Wei J; Zhou L
Mol Med Rep; 2016 Sep; 14(3):2171-9. PubMed ID: 27430155
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
[TBL] [Abstract][Full Text] [Related]
6. Cinchonine inhibits osteoclast differentiation by regulating TAK1 and AKT, and promotes osteogenesis.
Jo YJ; Lee HI; Kim N; Hwang D; Lee J; Lee GR; Hong SE; Lee H; Kwon M; Kim NY; Kim HJ; Park JH; Kang YH; Kim HS; Lee SY; Jeong W
J Cell Physiol; 2021 Mar; 236(3):1854-1865. PubMed ID: 32700766
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6.
Singh AK; Umar S; Riegsecker S; Chourasia M; Ahmed S
Arthritis Rheumatol; 2016 Feb; 68(2):347-58. PubMed ID: 26473505
[TBL] [Abstract][Full Text] [Related]
8. TRAF6 promotes myogenic differentiation via the TAK1/p38 mitogen-activated protein kinase and Akt pathways.
Xiao F; Wang H; Fu X; Li Y; Wu Z
PLoS One; 2012; 7(4):e34081. PubMed ID: 22496778
[TBL] [Abstract][Full Text] [Related]
9. The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.
Schnetzke U; Fischer M; Kuhn AK; Spies-Weisshart B; Zirm E; Hochhaus A; Müller JP; Scholl S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):605-15. PubMed ID: 23263202
[TBL] [Abstract][Full Text] [Related]
10. A Dithiol Compound Binds to the Zinc Finger Protein TRAF6 and Suppresses Its Ubiquitination.
Koga R; Radwan MO; Ejima T; Kanemaru Y; Tateishi H; Ali TFS; Ciftci HI; Shibata Y; Taguchi Y; Inoue JI; Otsuka M; Fujita M
ChemMedChem; 2017 Dec; 12(23):1935-1941. PubMed ID: 28884970
[TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide-dependent kinase-1 inhibits TRAF6 ubiquitination by interrupting the formation of TAK1-TAB2 complex in TLR4 signaling.
Moon G; Kim J; Min Y; Wi SM; Shim JH; Chun E; Lee KY
Cell Signal; 2015 Dec; 27(12):2524-33. PubMed ID: 26432169
[TBL] [Abstract][Full Text] [Related]
12. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.
Sorrentino A; Thakur N; Grimsby S; Marcusson A; von Bulow V; Schuster N; Zhang S; Heldin CH; Landström M
Nat Cell Biol; 2008 Oct; 10(10):1199-207. PubMed ID: 18758450
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of heat shock protein 27 antagonizes TNF-α induced HeLa cell apoptosis via regulating TAK1 ubiquitination and activation of p38 and ERK signaling.
Qi Z; Shen L; Zhou H; Jiang Y; Lan L; Luo L; Yin Z
Cell Signal; 2014 Jul; 26(7):1616-25. PubMed ID: 24686082
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor receptor-associated factor 6 contributes to malignant behavior of human cancers through promoting AKT ubiquitination and phosphorylation.
Shi J; Liu Z; Xu Q
Cancer Sci; 2019 Jun; 110(6):1909-1920. PubMed ID: 30945383
[TBL] [Abstract][Full Text] [Related]
15. Chemical inhibition of TRAF6-TAK1 axis as therapeutic strategy of endotoxin-induced liver disease.
Kim SH; Baek SI; Jung J; Lee ES; Na Y; Hwang BY; Roh YS; Hong JT; Han SB; Kim Y
Biomed Pharmacother; 2022 Nov; 155():113688. PubMed ID: 36150308
[TBL] [Abstract][Full Text] [Related]
16. TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL.
Walsh MC; Kim GK; Maurizio PL; Molnar EE; Choi Y
PLoS One; 2008; 3(12):e4064. PubMed ID: 19112497
[TBL] [Abstract][Full Text] [Related]
17. Regulatory role of tumor necrosis factor receptor-associated factor 6 in breast cancer by activating the protein kinase B/glycogen synthase kinase 3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhou S; Chen X; Tang J
Mol Med Rep; 2017 Aug; 16(2):2269-2273. PubMed ID: 28627683
[TBL] [Abstract][Full Text] [Related]
18. (+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation.
Chiou WF; Huang YL; Liu YW
PLoS One; 2014; 9(2):e89159. PubMed ID: 24558484
[TBL] [Abstract][Full Text] [Related]
19. TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol.
Jakus PB; Kalman N; Antus C; Radnai B; Tucsek Z; Gallyas F; Sumegi B; Veres B
J Nutr Biochem; 2013 May; 24(5):819-23. PubMed ID: 22925919
[TBL] [Abstract][Full Text] [Related]
20. Oligomerization-primed coiled-coil domain interaction with Ubc13 confers processivity to TRAF6 ubiquitin ligase activity.
Hu L; Xu J; Xie X; Zhou Y; Tao P; Li H; Han X; Wang C; Liu J; Xu P; Neculai D; Xia Z
Nat Commun; 2017 Oct; 8(1):814. PubMed ID: 28993672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
